Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Valcárcel, María ^a   Mendoza, Lorea ^b   Hernández, José Julio ^b   Carrascal, Teresa ^b   Salado, Clarisa ^a   Crende, Olatz ^b   Vidal Vanaclocha, Fernando ^c  

^a Innoprot SL   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CELECOXIB; CYCLOOXYGENASE 2; NEUTRALIZING ANTIBODY; PROSTAGLANDIN E2; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT VASCULOTROPIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; LIPOPOLYSACCHARIDE; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW METASTASIS; BONE METASTASIS; CANCER SIZE; CELL ADHESION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; GROWTH REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; MELANOMA CELL; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; BONE MARROW CANCER; C57BL MOUSE; CULTURE MEDIUM; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL MELANOMA; MELANOMA; METABOLISM; METASTASIS; PATHOLOGY; STROMA CELL; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE MARROW; BONE MARROW NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLULAR MICROENVIRONMENT; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 2; HUMANS; LIPOPOLYSACCHARIDES; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; PYRAZOLES; STROMAL CELLS; SULFONAMIDES; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052032423     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-142     Document Type: Article

References (54)

1. Hawes D, Neville M, Cote RJ. Occult metastasis. Biomed Pharmacother 2001, 55:229-242. 10.1016/S0753-3322(01)00052-X, 11393810.
2. Berretoni BA, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg 1986, 68:308-312.
3. Fodstad O, Faye R, Hoifodt HK, Skovlund E, Aamdal S. Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Recent Results Cancer Res 2001, 158:40-50. 10.1007/978-3-642-59537-0_5, 11092032.
4. Sato S, Futakuchi M, Ogawa K, Asamoto M, Nakao K, Asai K, Shirai T. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment. Cancer Sci 2008, 99:316-23. 10.1111/j.1349-7006.2007.00690.x, 18271931.
5. Berdel WE, Danhauser-Riedl S, Steinhauser G, Winton EF. Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells. Blood 1990, 73:80-83.
6. Argüello F, Furlanetto RW, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Incidence and distribution of experimental metastases in mutant mice with defective organ microenvironments (Genotypes Sl/SId and W/Wv). Cancer Res 1992, 52:2304-2309.
7. Giunciuglio D, Cai T, Filanti C, Manduca P, Albini A. Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer Letters 1995, 97:69-74. 10.1016/0304-3835(95)03955-V, 7585480.
8. Sasaki A, Alcalde RE, Nishiyama A, Lim DD, Mese H, Akedo H, Matsumura T. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res 1998, 58:462-467.
9. Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocrine-Related Cancer 1999, 6:333-347. 10.1677/erc.0.0060333, 10516850.
10. Mundy GR, Martin TJ. Pathophysiology of skeletal complications of cancer. Handbook of Experimental Pharmacology. Physiology and Pharmacology of Bone 1993, 107:641-671. Berlin: Springer-Verlag, Mundy GR, Martin TJ.
11. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Critical Reviews in Oncology/Hematology 1995, 18:51-64. 10.1016/1040-8428(94)00122-A, 7535057.
12. Gleave ME, Hsieh JT, Von Eschenbach AC, Chung LW. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. Journal of Urology 1992, 147:1151-1159.
13. Juneja HS, Schmalsteig FC, Lee S, Chen J. Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol 1993, 21:444-450.
14. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Biphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995, 55:3551-3557.
15. Michigami T, Dallas SL, Mundy GR, Yoneda T. Interactions of myeloma cells with bone marrow stromal cells via alpha4beta1 integrin-VCAM-1 is required for the development of osteolysis. Journal of Bone and Mineral Research 1997, 12:S128.
16. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, Levine AC. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis 1999, 17:687-694. 10.1023/A:1006728119549, 10919714.
17. Ono K, Akatsu T, Murakami T, Kitamura R, Yamamoto M, Shinomiya N, Rokutanda M, Sasaki T, Amizka N, Ozawa H, Nagata N, Kugai N. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 2002, 17:774-781. 10.1359/jbmr.2002.17.5.774, 12009007.
18. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991-994.
19. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999, 59:987-990.
20. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997, 57:1276-80.
21. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716. 10.1016/S0092-8674(00)81433-6, 9630216.
22. Denkert C, Köbel M, Berger S, Siegert A, Leclere A, Trefzer U, Hauptmann S. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001, 61:303-308.
23. Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, Bangert J, Harmon JM, Fujiwara H, Koki A Nelson MA. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003, (2):713-8.
24. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker?. Melanoma Res 2009, 19:8-16. 10.1097/CMR.0b013e32831d7f52, 19430402.
25. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000, 60:1306-11.
26. Anasagasti MJ, Olaso E, Calvo F, Mendoza L, Martin JJ, Bidaurrazaga J, Vidal-Vanaclocha F. Interleukin 1-dependent and -independent mouse melanoma metastases. J Natl Cancer Inst 1997, 89:645-51. 10.1093/jnci/89.9.645, 9150189.
27. Wang HH, Mcintosh AR, Hasinoff BB, MacNeil B, Rector E, Nance DM, Orr FW. Regulation of B16F1 melanoma cell metastasis by inducible functions of the hepatic microvasculature. Eur J Cancer 2002, 38:1261-70. 10.1016/S0959-8049(02)00039-4, 12044514.
28. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297-305. 10.1016/j.ccr.2004.08.012, 15380520.
29. Vidal-Vanaclocha F, Amézaga C, Asumendi A, Kaplanski G, Dinarello CA. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases. Cancer Res 1994, 54:2667-2672.
30. Haq M, Goltzman D, Tremblay G, Brodt P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 1992, 52:4613.
31. Vidal-Vanaclocha F, Alvarez A, Asumendi A, Urcelay B, Tonino P, Dinarello CA. Interleukin-1 (IL-1)-dependent melanoma hepatic metastasis in vivo; increased endothelial adherence by IL-1-induced mannose receptors and growth factor production in vitro. J Natl Cancer Inst 1996, 88:198-205. 10.1093/jnci/88.3-4.198, 8632494.
32. Martin-Padura I, Mortarini R, Lauri D, Bernasconi S, Sanchez-Madrid F, Parmiani G, Mantovani A, Anichini A, Dejana E. Heterogeneity in human melanoma cell adhesion to cytokine activated endothelial cells correlates with VLA-4 expression. Cancer Res 1991, 51:2239-41.
33. Zhang Y, Oh-hara T, Morinaga Y, Nakagawa T, Yamada M, Tsuruo T. Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis. Oncogene 1998, 16:693-703. 10.1038/sj.onc.1201581, 9488033.
34. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997, 89:1870-1875.
35. Pelletier L, Regnard J, Fellmann D, Charbord P. An in vitro model for the study of human bone marrow angiogenesis: role of hematopoietic cytokines. Lab Invest 2000, 80:501-511.
36. Rofstad EK, Danielsen T. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 1998, 77:897-902. 10.1038/bjc.1998.148, 2150085, 9528831.
37. Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001, 159:223-235. 10.1016/S0002-9440(10)61688-4, 1850434, 11438469.
38. Ghossein RA, Coit D, Brennan M, Zhang ZF, Wang Y, Bhattacharya S, Houghton A, Rosai J. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 1998, 4:419-28.
39. Mundy GR. Mechanism of bone metastasis. Cancer 1997, 15:1546-1556.
40. Argüello F, Baggs BB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988, 48:6876-6881.
41. Argüello F, Baggs RB, Graves BT, Harwell SE, Cohen HJ, Frantz CN. Effect of IL-1 on experimental bone/bone marrow metastases. Int J Cancer 1992, 52:802-810. 10.1002/ijc.2910520522, 1428234.
42. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-147.
43. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Massini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001, 3:53-61. 10.1038/sj.neo.7900127, 1505025, 11326316.
44. Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH. Antimetastatic activity of a cyclooxygenase-2 inhibitor. BJC 2004, 91:359-365. 2409822, 15213717.
45. Pérez M, Migliaccio S, Taranta A, Festuccia C, Orru L, Brama M, Bologna M, Faraggiana T, Baron R, Teti A. Melanoma cells stimulate osteoclastogenesis, c-Src expression and osteoblast cytokines. Eur J Cancer 2001, 37:629-640. 10.1016/S0959-8049(00)00436-6, 11290439.
46. Kakiuchi Y, Tsuji S, Tsujii M, Murata H, Kawai N, Yasumaru M, Kimura A, Komori M, Irie T, Miyoshi E, Sasaki Y, Hayashi N, Kawano S, Hori M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002, 62:1567-1572.
47. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002, 190:279-286. 10.1002/jcp.10068, 11857443.
48. Schadendorf D, Heidel J, Gawlik C, Suter L, Czarnetzki BM. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995, 87:366-371. 10.1093/jnci/87.5.366, 7531774.
49. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi GM, Cacciola E, Sortino G, Guglielmo P, Giustolisi R. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001, 15:976-980. 10.1038/sj.leu.2402124, 11417486.
50. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M, Hicklin DJ, Zhu Z, Witte L, Crystal RG, Moore MA, Rafii S. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001, 193:1005-1014. 10.1084/jem.193.9.1005, 2193424, 11342585.
51. Mendoza L, Valcarcel M, Carrascal T, Egilegor E, Salado C, Sim BK, Vidal-Vanaclocha F. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 2004, 64:304-10. 10.1158/0008-5472.CAN-03-1829, 14729638.
52. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997. 10.1038/nm0996-992, 8782456.
53. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, Ferri LE. LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Res 2011, 71:1989-98. 10.1158/0008-5472.CAN-10-2833, 21363926.
54. Harmey JH, Bucana CD, Lu W, Byrne AM, Mcdonnell S, Lynch C, Bouchier-Hayes D, Dong Z. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002, 101:415-22. 10.1002/ijc.10632, 12216068.